A Composite Serum Biomarker Index for the Diagnosis of Systemic Sclerosis–Associated Interstitial Lung Disease: A Multicenter, Observational Cohort Study

Jee, AS; Stewart, I; Youssef, P; Adelstein, S; Lai, D; Hua, S; Stevens, W; Proudman, S; Ngian, GS; Glaspole, IN; Moodley, YP; Bleasel, JF; Macansh, S; Nikpour, M; Sahhar, J; Corte, TJ; Australian Scleroderma Cohort Study, Australian Scleroderma Interest Group, Australian Idiopathic Pulmonary Fibrosis Registry, and associated investigators

doi:10.1002/art.42491

Systemic sclerosis & Raynaud's

A Composite Serum Biomarker Index for the Diagnosis of Systemic Sclerosis–Associated Interstitial Lung Disease: A Multicenter, Observational Cohort Study

Arthritis RheumatolPublished 15 May 2023Diagnostic accuracy study

Performance · SSc-ILD diagnosis, biomarker index score 3ResultPooled adjusted odds ratio 12.72 95% CI 4.59–35.21

Read the original article ↗PubMed

Cite

Authors' conclusion

A composite serum biomarker index, comprising SP-D, Ca15-3, and ICAM-1, may improve the identification and risk stratification of ILD in SSc patients at baseline.

Study context

Population: Patients with systemic sclerosis (SSc) with or without ILD, patients with idiopathic pulmonary fibrosis, and healthy controls; Australia28 biomarkers analysed
Participants: 640 patients

Comparison: Composite serum biomarker index for identifying SSc-ILD
SSc-ILDn = 259
SSc without ILDn = 179
IPF-controlsn = 172
Healthy controlsn = 30
Outcome: Performance of a composite biomarker index to identify ILD, specifically SSc-ILD

Methodological detailsmulticenter, observational cohort, derivation and validation cohorts

Multicenter
Observational cohort
Derivation and validation cohorts

Performance

SSc-ILD diagnosis, biomarker index score 3

Pooled adjusted odds ratio

12.72

95% CI 4.59–35.21

P < 0.001

Biomarker index score 3

pooled aOR 12.72 (95% CI 4.59–35.21); P < 0.001

As reported in the abstract

Further findings

Outcome	Adjusted absolute change (%)	P value
Baseline disease severity in SSc patients: adjusted absolute change in FVC % predictedBiomarker index score 3 vs Biomarker index score 0	−17.84	P < 0.001
Baseline disease severity in SSc patients: adjusted absolute change in DLCO % predictedBiomarker index score 3 vs Biomarker index score 0	−20.16	P < 0.001

Reference

Authors: Jee AS, Stewart I, Youssef P, Adelstein S, Lai D, Hua S, et al.
All 17 authors
Jee AS, Stewart I, Youssef P, Adelstein S, Lai D, Hua S, Stevens W, Proudman S, Ngian GS, Glaspole IN, Moodley YP, Bleasel JF, Macansh S, Nikpour M, Sahhar J, Corte TJ, Australian Scleroderma Cohort Study, Australian Scleroderma Interest Group, Australian Idiopathic Pulmonary Fibrosis Registry, and associated investigators
Journal: Arthritis & Rheumatology
Published: 15 May 2023
DOI: 10.1002/art.42491
PubMed: 36908055

Topic: Systemic sclerosis & Raynaud's

Comparison

Composite serum biomarker index (surfactant protein D (SP-D), Ca15-3, ICAM-1) for identifying SSc-ILD

Diagnostic definitions

SSc-ILD: patients with SSc-ILD (Australian Scleroderma Cohort Study)
SSc without ILD: SSc patients without ILD (Australian Scleroderma Cohort Study)
IPF-controls: patients with idiopathic pulmonary fibrosis (Australian IPF Registry)

Key notes

The composite index strengthened the performance of individual biomarkers for SSc-ILD identification
Independent of age, sex, smoking history, and lung function

Original publication

A Composite Serum Biomarker Index for the Diagnosis of Systemic Sclerosis–Associated Interstitial Lung Disease: A Multicenter, Observational Cohort Study. Arthritis Rheumatol. Published 15 May 2023. doi:10.1002/art.42491

Read the original article ↗

Composed by AI from the published abstract and checked against it. How Briefs are made →